Kailera Therapeutics (NASDAQ:KLRA) Upgraded by Jefferies Financial Group to “Strong-Buy” Rating

Kailera Therapeutics (NASDAQ:KLRA) was upgraded by equities research analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. William Blair initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating for the company. Wall Street Zen raised Kailera Therapeutics to a “hold” rating in a report on Saturday, April 25th. JPMorgan Chase & Co. initiated coverage on Kailera Therapeutics in a report on Tuesday. They set an “overweight” rating and a $30.00 target price for the company. Leerink Partners initiated coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $36.00 price target for the company. Finally, TD Cowen began coverage on Kailera Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $57.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to MarketBeat, Kailera Therapeutics presently has an average rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Performance

Shares of KLRA opened at $22.30 on Tuesday. Kailera Therapeutics has a twelve month low of $20.86 and a twelve month high of $28.23.

Insider Buying and Selling

In related news, major shareholder Rtw Investments, Lp acquired 500,000 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The shares were bought at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the purchase, the insider directly owned 10,776,820 shares in the company, valued at $172,429,120. The trade was a 4.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Adam Koppel acquired 1,562,500 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the completion of the purchase, the director owned 22,583,268 shares of the company’s stock, valued at $361,332,288. This trade represents a 7.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 10,460,938 shares of company stock valued at $167,375,008 over the last ninety days.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.